Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Heart rate corrected peak O2 pulse as a significant predictor of cardiovascular adverse events in Heart Failure patients
Session:
Best Posters
Speaker:
Catarina Lagoas Pohle
Congress:
CPC 2024
Topic:
J. Preventive Cardiology
Theme:
29. Rehabilitation and Sports Cardiology
Subtheme:
29.1 Exercise Testing
Session Type:
Cartazes
FP Number:
---
Authors:
Catarina Lagoas Pohle; Rita Almeida Carvalho; Joana Silva Ferreira; Rui Antunes Coelho; Jéni Quintal; Patrícia Bernardes; Anaí Durazzo; Miguel Mendes; Catarina Sá; Filipe Seixo; Gonçalo Lopes da Cunha
Abstract
<p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Introduction </strong></span></span></span></p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">Peak O2 pulse (O2P) is a Cardiopulmonary Exercise Testing (CPET) parameter that reflects stroke volume. It is known that patients with chronotropic incompetence have increased time for diastole and, thus, falsely increased stroke volume, which frequently leads to normal or supranormal O2P values in this patient population. Peak O2 pulse has previously demonstrated its role as a predictor of adverse cardiovascular (CV) events. However, the inability to reach the predicted maximum heart rate (HR) may underestimate the ability of this variable to predict events. </span></span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Aim</strong></span></span></span></p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">We aimed to observe in a population of patients with Heart Failure (HF) whether a correction for peak O2P to the predicted maximal heart rate (HR) percentage can be used as a predictor of major adverse CV events (MACE).</span></span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Methods</strong></span></span></span></p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">A retrospective observational study was conducted with a sample of HF patients with ejection fraction <50% who underwent CPET on a treadmill. Peak O2 pulse and maximal HR were collected, predicted O2 pulse was calculated from Wasserman’s equation for predicted maximal oxygen uptake and predicted HR was calculated from Astrand’s formula. The corrected O2P was obtained by dividing the measured peak OP2 by the percentage of the predicted maximal HR for age attained (Figure 1-A). Cox regression analysis was performed to assess possible associations with the intended outcomes (CV death, urgent heart transplantation, left ventricular assist device and HF hospitalization).</span></span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Results</strong></span></span></span></p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">A total of 248 patients with HF were included (17.3% were women), with a mean age of 58.3 ± 11.4 years. The etiology of HF was ischemic in 66.5% of patients, with a mean ejection fraction of 34± 10% and a median NT-proBNP value of 744 micrograms/dL (IQR 241 to 2255). The median peak O2P value measured was 11.5 mL/beat (IQR 9.0 to 14.2), which corresponds to 87.1% (IQR 69.4 to 105.6) of the predicted O2P. The mean corrected O2P was 8.7 ± 3.2 mL/beat, corresponding to 64.8 ± 21% of the predicted O2P.</span></span></span></p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">In univariate analysis for the primary endpoint, the Wald Chi square value was greater for the percentual corrected O2P (Wald 90.414, p < 0.001), followed by the corrected O2P (Wald 68.922, p < 0.001), percentual measured O2P (Wald 44.176, p < 0.001) and measured peak O2P (Wald 1.827, p = 0.176) (Figure 1-B). </span></span></span></p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">Percentual corrected O2P remained significantly associated with the primary endpoint (HR 0.970 [95% CI 0.955 to 0.985; p < 0.001] even when adjusted for NT-proBNP, VE/VCO2 slope and Peak oxygen uptake (pVO2). Furthermore, percentual corrected O2P was the strongest parameter in multivariate analysis, outperforming even VE/VCO2 slope and pVO2 for the prediction of events (Figure 1-B).</span></span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Conclusion</strong></span></span></span></p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">This study suggests that corrected O2P and percentual corrected O2P could be used as strong MACEs predictors. Additionally, percentual corrected O2P showed an even greater ability to predict adverse outcomes in HF patients than NT-proBNP, VE/VCO2 slope and pVO2.</span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site